Blue Cloud Softech secures key endorsements for healthcare expansion

Blue Cloud Softech Solutions Limited (BSE: 539607) announced its international expansion into Commonwealth countries, introducing its BluBio, BluHealth, and Bioster healthcare products. This initiative follows prestigious endorsements from the Commonwealth Medical Association (CMA) and the Indian Medical Association (IMA), representing over 1.5 million healthcare professionals globally. The company aims to address healthcare challenges by providing accessible, integrated solutions across Africa, Asia, the Caribbean, and Pacific regions.

The Commonwealth healthcare technology market presents a substantial opportunity of $957 billion for Blue Cloud's product portfolio. This includes an $85 billion market for BluBio (biobanking and precision diagnostics), a $78 billion market for BluHealth (digital health platform), and a $29.3 billion market for Bioster (environmental safety and air purification). The expansion leverages strategic advantages such as English language commonality, regulatory harmonization, and significant digital infrastructure growth across the 56 Commonwealth nations.

BluBio maintains over 150,000 unique specimens with an asset value exceeding $50 million. BluHealth integrates AI-based screening, IoT diagnostics, and clinic/hospital management systems. Bioster, backed by 10 years of R&D, offers advanced nano-photocatalytic air and surface purification, boasting 99% germ-free performance and zero secondary pollution.